Browse the evidence

A multifactorial approach targeting glucose, blood pressure, lipids, and lifestyle simultaneously is the most effective strategy for preventing diabetes complications.

To prevent serious health issues, you need to manage your blood sugar, blood pressure, and cholesterol together, not just one. This involves lifestyle changes like eating well, exercising 150 minutes a week, and losing weight, often supported by medications. This combined approach is proven to be the best way to protect your heart and kidneys.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and greater weight loss compared to selective GLP-1 agonists (semaglutide) and basal insulins (degludec, glargine) in patients with type 2 diabetes.

Tirzepatide is a once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1) to improve how your body handles sugar and fat. Clinical trials show it lowers blood sugar and reduces body weight more effectively than standard diabetes medications like insulin or other GLP-1 drugs like semaglutide. It is prescribed for adults with type 2 diabetes or obesity, starting at a low dose to minimize stomach upset, and increasing over time. It is not suitable for people with a specific family history of thyroid cancer.

Tirzepatide induces significant weight loss (up to 20.4% with 15mg dose) in individuals with overweight or obesity, comparable to effects observed with bariatric surgery.

For individuals with obesity, tirzepatide offers a non-surgical path to significant weight loss. In clinical trials, the highest dose resulted in an average loss of over 20% of body weight, which is comparable to the results typically seen with bariatric surgery. This makes it a powerful alternative for those who cannot undergo or prefer to avoid surgery.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) produce significant weight loss in adults with obesity, primarily through central appetite suppression and delayed gastric emptying, with efficacy varying by specific agent and dose.

GLP-1 agonists like semaglutide (2.4mg weekly) and liraglutide (1.8mg daily) are highly effective for weight loss, significantly outperforming lifestyle changes alone. They work by slowing digestion and reducing hunger signals in the brain. While effective, they require chronic use to maintain weight loss, and side effects like nausea are common.

Dual incretin agonists (GLP-1/GIP) such as tirzepatide demonstrate superior weight loss efficacy compared to single GLP-1 agonists.

Tirzepatide (15mg weekly) is a dual-acting drug (GLP-1/GIP) that produces greater weight loss (~21%) than single-acting GLP-1 drugs. It is currently approved for type 2 diabetes and under review for obesity. It requires weekly injection and medical supervision.

Switching from saturated and trans fats to unsaturated fats (MUFAs and PUFAs) in the diet causally reduces plasma LDL particle concentration, thereby reducing the risk of atherosclerotic cardiovascular disease (ASCVD).

To lower your risk of heart disease, focus on swapping the types of fat you eat. Replace saturated fats (found in butter, fatty meats, full-fat dairy) and trans fats with unsaturated fats (found in olive oil, nuts, seeds, and fatty fish). This substitution lowers LDL cholesterol, which is a primary driver of heart disease. You don't need to eliminate fat; just choose higher-quality sources.

Once-weekly 2.4 mg semaglutide produces significant weight loss and cardiometabolic improvements in adults with obesity, regardless of whether the treatment is combined with standard or very intensive lifestyle interventions.

Take 2.4 mg of semaglutide once weekly, starting with a low dose (0.25 mg) and increasing every 4 weeks to minimize side effects. While you should still eat healthy and exercise, do not expect lifestyle changes to significantly boost weight loss beyond what the medication provides. The drug itself is the primary driver of weight loss.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce substantial weight loss (up to 20%) by acting on CNS neural circuits, specifically the dorsal vagal complex.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, often resulting in 10-20% body weight reduction. They work by acting on brain circuits that control appetite. You must take them chronically, as stopping leads to weight regain. Side effects like nausea are common but manageable.

An intensive lifestyle intervention (ILS) focused on weight loss and increased physical activity reduces the incidence of type 2 diabetes by 58% compared to placebo in high-risk adults with prediabetes, with effects sustained over 21 years.

To significantly lower your risk of developing type 2 diabetes, focus on losing 7% of your body weight and getting at least 150 minutes of moderate physical activity per week. This lifestyle approach is proven to be more effective than medication (metformin) for preventing diabetes in high-risk individuals, with benefits lasting for decades.

Metformin (850 mg twice daily) reduces the incidence of type 2 diabetes by 31% compared to placebo in high-risk adults, with greater efficacy in individuals with a BMI >= 35 kg/m2 and fasting glucose 110–125 mg/dL.

If you are at high risk for type 2 diabetes, metformin (850 mg twice daily) can reduce your risk by 31%. However, it is most effective if you have a BMI of 35 or higher or a fasting glucose between 110-125 mg/dL. Lifestyle changes remain more effective overall.

Intensive, long-term behavioral lifestyle interventions can achieve and sustain clinically meaningful weight loss (4-5% reduction) in adults with type 2 diabetes, contrary to the common expectation that most lost weight is regained within 3-5 years.

To maintain significant weight loss long-term, you need more than just a diet plan; you need an intensive, ongoing behavioral program. This includes regular self-monitoring (like weighing yourself), dietary adjustments, physical activity, and problem-solving strategies delivered through consistent support (group or individual). The key is that the intervention must be 'intensive' and 'ongoing' to counteract the natural tendency to regain weight.

Intensive lifestyle interventions produce comparable long-term weight loss outcomes across different racial, ethnic, and gender groups, refuting the assumption that non-white participants achieve poorer outcomes.

If you are from a minority racial or ethnic background, or if you are a man, know that intensive lifestyle interventions can be just as effective for you as for others. The key is engaging with the behavioral strategies provided.

Intensive behavioral lifestyle interventions (combining caloric restriction, structured physical activity, and behavioral counseling) produce significant, sustained weight loss (average 4.7% at 8 years) and improve metabolic health outcomes in overweight/obese individuals with Type 2 Diabetes, refuting the belief that meaningful long-term behavioral weight loss is unsustainable.

To sustain weight loss with Type 2 Diabetes, you need more than just willpower; you need a structured system. Start with weekly check-ins (group or individual) to set specific, small goals for diet and activity. Use tools like meal replacements or strict meal plans to remove the daily decision fatigue of 'what to eat.' Track your progress (weight, food, activity) not to judge yourself, but to identify problems early. Aim for 175 minutes of moderate activity per week, broken into small chunks (e.g., 10-minute walks). Remember, the goal is not perfection, but consistent adherence to a system that supports your health.

Intensive lifestyle interventions improve Type 2 Diabetes remission rates and reduce medication usage, even if they do not significantly reduce cardiovascular mortality events compared to standard care.

Even if your weight loss isn't dramatic enough to eliminate all cardiovascular risk factors, the metabolic benefits of lifestyle change are profound. You can achieve diabetes remission (normal blood sugar without meds) and significantly reduce your reliance on glucose-lowering and blood pressure medications. Work with your doctor to adjust medications as you lose weight to avoid side effects like hypoglycemia. The goal is to improve your metabolic health, which often happens before major cardiovascular events are prevented.

Once-weekly subcutaneous semaglutide at 2.4mg induces significant weight loss (mean 14.9%) in adults with obesity, significantly outperforming placebo.

For adults with obesity, once-weekly subcutaneous semaglutide at 2.4mg is a highly effective treatment for weight loss, averaging a 14.9% reduction in body weight over 68 weeks when combined with lifestyle changes. This is significantly better than placebo. Patients should expect potential gastrointestinal side effects, which are usually temporary, and adhere to the titration schedule to minimize them.

Once-weekly subcutaneous semaglutide at 1.0mg significantly lowers HbA1c and promotes weight loss in patients with Type 2 Diabetes compared to other glucose-lowering therapies.

For patients with Type 2 Diabetes, once-weekly subcutaneous semaglutide at 1.0mg is a highly effective treatment for lowering HbA1c (reducing it by 1.6-1.9%) and promoting weight loss. It is superior to other common glucose-lowering medications and even other GLP-1 RAs like dulaglutide in head-to-head comparisons.

Trans fats are harmful and should be eliminated, while saturated fat's impact depends on the food matrix and what it replaces.

Eliminate trans fats completely. For saturated fats, focus on the food source (e.g., cheese, nuts) rather than just the fat content, and ensure you are replacing them with unsaturated fats, not refined carbs.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce 15–25% mean weight loss and reduce cardiovascular events by 20% and type 2 diabetes incidence by 72%.

If you have obesity or overweight with a related health condition, GLP-1 medications like semaglutide (Wegovy) or tirzepatide (Zepbound) are currently the most effective pharmacological treatments, offering 15-25% weight loss and significant cardiovascular benefits. These require weekly injections (or oral forms for some) and work best when combined with a modest caloric deficit and regular exercise. Be aware of potential gastrointestinal side effects and the need for long-term management, as stopping the medication often leads to weight regain.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves higher mean weight loss (up to 20.9%) than selective GLP-1 agonists.

Tirzepatide (Zepbound) is a once-weekly injection that targets both GIP and GLP-1 receptors, resulting in an average 20.9% weight loss over 72 weeks, which is higher than semaglutide. It is indicated for adults with obesity or overweight with comorbidities. Like other GLP-1 agonists, it requires lifestyle changes and may cause gastrointestinal side effects. Access may be limited by cost and insurance coverage.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces HbA1c (by 1.7–2.4%) and body weight (up to 22.5%) in patients with type 2 diabetes compared to placebo, semaglutide, and insulin therapies.

Tirzepatide is a once-weekly injection for type 2 diabetes that significantly lowers blood sugar and promotes substantial weight loss. It starts at a low dose (2.5 mg) to minimize stomach issues, then increases every 4 weeks up to 15 mg. It is more effective for weight loss and A1C reduction than insulin or semaglutide in head-to-head trials. Common side effects are gastrointestinal (nausea, diarrhea) but are usually mild. It is contraindicated for those with a history of medullary thyroid carcinoma.

Lifestyle modifications, specifically Mediterranean diet and moderate aerobic exercise, are the cornerstone for managing insulin resistance and improving cardiovascular outcomes.

Start with the basics: eat a Mediterranean-style diet (lots of veggies, whole grains, healthy fats) and aim for 150 minutes of moderate exercise per week. This is the most effective way to improve insulin sensitivity and protect your heart, serving as the foundation for any medication you might take.

Intensive lifestyle intervention leads to significant long-term weight loss and improvements in microvascular complications (diabetes remission, kidney disease, sleep apnea) in individuals with type 2 diabetes, despite failing to reduce macrovascular cardiovascular events.

Focus on the tangible benefits of weight loss for your diabetes management, such as better blood sugar control, reduced need for medication, and improved quality of life. These benefits are real and significant, even if weight loss doesn't directly prevent heart attacks.

GLP-1 receptor agonists (GLP-1 RAs) produce significant weight loss (7–24%) and HbA1c reductions (1.5–2.0%) through pleiotropic mechanisms including enhanced mitochondrial function, anti-inflammatory actions, and improved cellular quality control.

GLP-1 medications are highly effective for weight loss and blood sugar control. They work through multiple biological pathways, not just hunger suppression. Newer oral versions exist for those who prefer pills over injections. Consult a doctor to determine the right agent and dose for your specific health profile.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide) reduce major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and cardiovascular mortality in patients with type 2 diabetes and established cardiovascular disease, as well as in non-diabetic patients with obesity and cardiovascular disease.

If you have Type 2 Diabetes and heart disease, or obesity and heart disease, GLP-1 agonists like semaglutide or liraglutide are proven to significantly lower your risk of heart attack, stroke, and heart-related death. This benefit exists alongside blood sugar control. Discuss with your doctor if you are a candidate, considering the cost and injection/oral delivery options.